Korsana Biosciences Shares Outstanding History (KRSA)
Korsana Biosciences reported 3.8M shares outstanding at the end of fiscal 2025.
View full Korsana Biosciences company overviewKorsana Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 3.8M | 1.3M | +50.09% |
| 2024 | 2024-12-31 | 2.5M | 71,763 | +2.90% |
| 2023 | 2023-12-31 | 2.5M | 298,223 | +13.71% |
| 2022 | 2022-12-31 | 2.2M | 5,426.75 | +0.25% |
| 2021 | 2021-12-31 | 2.2M | 468,144.25 | +27.50% |
| 2020 | 2020-12-31 | 1.7M | 322,458.35 | +23.37% |
| 2019 | 2019-12-31 | 1.4M | — | — |
Korsana Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.3M | 1.2M | +38.37% |
| Q1 2026 | 2026-03-31 | 4.2M | 1.2M | +38.56% |
| Q4 2025 | 2025-12-31 | 3.8M | 1.3M | +50.09% |
| Q3 2025 | 2025-09-30 | 3.7M | 1.2M | +46.00% |
| Q2 2025 | 2025-06-30 | 3.1M | 560,094 | +22.26% |
| Q1 2025 | 2025-03-31 | 3.1M | 561,343 | +22.46% |
| Q4 2024 | 2024-12-31 | 2.5M | 71,763 | +2.90% |
| Q3 2024 | 2024-09-30 | 2.5M | 85,802 | +3.51% |
| Q2 2024 | 2024-06-30 | 2.5M | 108,078 | +4.49% |
| Q1 2024 | 2024-03-31 | 2.5M | 323,356.3 | +14.86% |
| Q4 2023 | 2023-12-31 | 2.5M | 298,223 | +13.71% |
| Q3 2023 | 2023-09-30 | 2.4M | 270,386.8 | +12.43% |
| Q2 2023 | 2023-06-30 | 2.4M | 233,804.25 | +10.75% |
| Q1 2023 | 2023-03-31 | 2.2M | 3,826.7 | +0.18% |
| Q4 2022 | 2022-12-31 | 2.2M | 5,426.75 | +0.25% |
| Q3 2022 | 2022-09-30 | 2.2M | 9,204.75 | +0.43% |
| Q2 2022 | 2022-06-30 | 2.2M | 10,229.3 | +0.47% |
| Q1 2022 | 2022-03-31 | 2.2M | 465,921.75 | +27.30% |
| Q4 2021 | 2021-12-31 | 2.2M | 468,144.25 | +27.50% |
| Q3 2021 | 2021-09-30 | 2.2M | 467,426.7 | +27.53% |
| Q2 2021 | 2021-06-30 | 2.2M | 770,876.95 | +55.34% |
| Q1 2021 | 2021-03-31 | 1.7M | 318,751.55 | +22.97% |
| Q4 2020 | 2020-12-31 | 1.7M | 322,458.35 | +23.37% |
| Q3 2020 | 2020-09-30 | 1.7M | 324,655.5 | +23.64% |
| Q2 2020 | 2020-06-30 | 1.4M | 22,326.05 | +1.63% |
| Q1 2020 | 2020-03-31 | 1.4M | 17,661.7 | +1.29% |
| Q4 2019 | 2019-12-31 | 1.4M | — | — |
| Q3 2019 | 2019-09-30 | 1.4M | — | — |
| Q2 2019 | 2019-06-30 | 1.4M | — | — |
| Q1 2019 | 2019-03-31 | 1.4M | — | — |
Korsana Biosciences Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Korsana Biosciences share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Korsana Biosciences used $130,000 to repurchase common stock in fy 2025. Across the latest 2 reported fiscal years, total share repurchases were $130,000.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2025 | 2025-12-31 | $130,000 |
| 2024 | 2024-12-31 | $0 |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Korsana Biosciences shares outstanding trends
Over the last five fiscal years, Korsana Biosciences's shares outstanding moved from 1.7M to 3.8M, a change of 2.1M. The latest reported quarter, Q2 2026, shows 4.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Korsana Biosciences source filings ↗